Clinical benefit of cancer drugs approved in Switzerland 2010-2019.

Publication

Clinical benefit of cancer drugs approved in Switzerland 2010-2019.

Journal Paper/Review - Jun 10, 2022

Adam Roman, Tibau Ariadna, Molto Valiente Consolación, Seruga Bostjan, Ocana Alberto, Amir Eitan, Templeton Arnoud J

Citation

Adam R, Tibau A, Molto Valiente C, Seruga B, Ocana A, Amir E, Templeton A. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PloS one 2022; 17:e0268545.

Type

Journal Paper/Review (English)

Journal

PloS one 2022; 17

Publication Date

Jun 10, 2022

Issn Electronic

1932-6203

Pages

e0268545

Brief description/objective

It is unknown to what extent cancer drugs approved in Switzerland by the Swissmedic fulfil criteria of clinical benefit according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS), the American Society of Clinical Oncology Value Framework version 2 (ASCO-VF) and the Swiss OLUtool v2 (OLUtool).